+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis



Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis



Diabetes Research and Clinical Practice 120: 31-39



Aspirin use for primary prevention of cardiovascular disease (CVD) is controversial, especially in patients with diabetes. The objective of this meta-analysis was to evaluate aspirin's safety and efficacy for primary prevention of CVD [fatal or nonfatal myocardial infarction (MI), fatal or nonfatal stroke, angina, transient ischemic attack (TIA), peripheral artery disease (PAD) and revascularization] in patients with diabetes. A literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD. Study sample size, and ischemic and bleeding events were extracted and analyzed using RevMan 5.2.7. In total, 6 studies (n=10,117) met criteria. Aspirin doses ranged from 100mg every other day to 650mg daily. Follow-up ranged from 3.6 to 10.1years. In patients with diabetes, there was no difference between aspirin and placebo with respect to the risk of all cause mortality (OR 0.93, 95% CI 0.81-1.06), or individual atherosclerotic events compared to placebo. There were no differences in bleeding (OR 2.53, 95% CI 0.77-8.34), GI bleeding (OR 2.14, 95% CI 0.63-7.33) or hemorrhagic stroke rates (OR 0.90, 0.34-2.33) between groups. It remains unclear whether aspirin may reduce the occurrence of a first atherosclerotic event or mortality in patients with diabetes. More research on this use of aspirin in patients with diabetes is required to supplement currently available research.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057236372

Download citation: RISBibTeXText

PMID: 27500549

DOI: 10.1016/j.diabres.2016.07.012


Related references

Primum non nocere: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. European Journal of Preventive Cardiology 2019: 2047487319826439, 2019

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice 87(2): 211-218, 2010

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on PharmacoTherapy 11(9): 1459-1466, 2010

Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. American Journal of the Medical Sciences 341(1): 1-9, 2011

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 32(12): 2300-2306, 2010

Erratum. Aspirin for the Primary Prevention of Cardiovascular Events. A Systematic Review and Meta-Analysis Comparing Patients With and Without Diabetes. Diabetes Care 2009;32:2300-2306. Diabetes Care: -, 2018

Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. American Journal of Medicine 129(5): E35-E36, 2016

Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. Plos One 9(10): E90286, 2016

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Bmj 339: B4531, 2009

Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. European Journal of Preventive Cardiology 2019: 2047487319825510-2047487319825510, 2019

Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine 34(3): 316-327, 2016

Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis 251: 177-182, 2017

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. American Heart Journal 162(1): 115-24.E2, 2011

Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Current Cardiology Reports 17(3): 566, 2015

Low-Dose Aspirin for the Primary Prevention of Cardiovascular Disease in Diabetic Individuals: A Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. Journal of Clinical Medicine 8(5), 2019